William R. Elder - Apr 18, 2022 Form 4 Insider Report for Diffusion Pharmaceuticals Inc. (DFFN)

Role
GC & Secretary
Signature
/s/ William R. Elder
Stock symbol
DFFN
Transactions as of
Apr 18, 2022
Transactions value $
$0
Form type
4
Date filed
4/19/2022, 05:17 PM
Previous filing
Mar 22, 2022
Next filing
Sep 15, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DFFN Common Stock Conversion of derivative security $2.5K +100 +33.33% $25.00* 400 Apr 18, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DFFN Series C Convertible Preferred Stock Conversion of derivative security -$2.5K -100 -100% $25.00* 0 Apr 18, 2022 Common Stock 100 $25.00 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 As previously announced, on March 18, 2022, the Reporting Person purchased 100 shares of Series C Convertible Preferred Stock, par value $0.001 per share (the "Series C Shares"), from the Issuer at a purchase price of $25.00 per Series C Share in a private placement. On April 18, 2022, in accordance with Section 8(a) of the Certificate of Designation of Preferences, Rights, and Limitations of the Series C Convertible Preferred Stock (the "Certificate of Designation"), the Issuer delivered to the Reporting Person written notice of the Mandatory Conversion (as defined in the Certificate of Designations) of all outstanding Series C Shares into an equivalent number of shares of the Company's common stock, par value $0.001, pursuant to and in accordance with the terms of the Certificate of Designation.
F2 All share and per share amounts have been adjusted to reflect the Issuer's 1-for-50 reverse stock split, effective April 18, 2022.